Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?

Diabetes Obes Metab. 2024 Apr;26(4):1150-1156. doi: 10.1111/dom.15459. Epub 2024 Jan 16.

Authors

Darren Lau¹, John-Michael Gamble²

Affiliations

¹ Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
² School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, Ontario, Canada.

PMID: 38229461
DOI: 10.1111/dom.15459

No abstract available

Keywords: GLP-1 analogue; antidiabetic drug; antiobesity drug; incretin therapy.

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Hypoglycemic Agents
Suicide*

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor